News and Events  Press Releases

 Back

SCYNEXIS Announces Broadening of Research Agreement With Roche For Discovery Of Novel Central Nervous System And Metabolic Disease Agents

RESEARCH TRIANGLE PARK, North Carolina, USA (September 12, 2003) - SCYNEXIS, Inc. announced today that it has broadened the scope and extended the term of its research agreement to discover and develop novel compounds for central nervous system and metabolic diseases with Roche. The transaction includes access by Roche to the SCYNEXIS MEDCHEM-FACTORY® technology and HEOS™ Hit Explorer Operating System software. This will accelerate the identification of novel leads against Roche's drug targets by producing large, focused, high-purity compound libraries and then utilizing rapid lead optimization to identify clinical candidates.

Specific financial terms were not disclosed. However, Roche will receive exclusive worldwide rights to products developed through the collaboration in exchange for technology access fees and other compensation for SCYNEXIS technologies and services.

“Roche is very pleased with the success of this collaboration. We are looking forward to a continued productive interaction with SCYNEXIS,” said Dr. Hans-Joachim Boehm, Head of Discovery Chemistry, Roche Basel.

“SCYNEXIS welcomes the expansion of its relationship with Roche. This is recognition of SCYNEXIS’ ability to accelerate the discovery of novel compounds for Roche through the combination of expertise and patented technologies,” said Dr. Yves J. Ribeill, President & CEO of SCYNEXIS.

About SCYNEXIS
SCYNEXIS is headquartered in Research Triangle Park, North Carolina with European operations, SCYNEXIS Europe Ltd., located near Cambridge, England. By combining its chemists' expertise with its proprietary MEDCHEM-FACTORY® technology and Hit Explorer Operating System (HEOS®), SCYNEXIS is increasing the productivity and speed of the pharmaceutical discovery process. As an innovator in the field of high-speed synthesis with special expertise in the area of automation, SCYNEXIS is reshaping the process of discovery and optimization of new, promising chemical compounds.

SCYNEXIS provides a full range of highly integrated synthetic chemistry processes and technologies to the life sciences industry - From Concept to Clinic™ - representing the next step in the industrialization of the drug discovery process. SCYNEXIS offers, in addition to its patented MEDCHEM-FACTORY® technology, novel hit generation compounds, hit explosion and lead optimization services as well as process optimization, the production of clinical samples in its GMP facility and radiochemistry synthesis services. For more information, please visit www.scynexis.com.

Media Contacts:

SCYNEXIS:
Rick Rountree
Rick Rountree Communications
(919) 878-1144
rick@rickrountree.com

Business Development Contacts:

SCYNEXIS:
In the U.S.:
Terry Marquardt
(919) 544-8600
terry.marquardt@scynexis.com
In Europe:
Dr. Hans Fliri
+ 44 (0) 1277 367 002
hans.firi@scynexis.com

Copyright © 2007. SCYNEXIS, INC